Milestone Scientific Gelecekteki Büyüme
Future kriter kontrolleri 1/6
Milestone Scientific kazanç ve gelirinin sırasıyla yıllık 21.5% ve 13.2% oranında artması tahmin edilirken, EPS'nin yıllık 26.1% oranında büyümesi bekleniyor.
Anahtar bilgiler
21.5%
Kazanç büyüme oranı
26.07%
EPS büyüme oranı
| Medical Equipment kazanç büyümesi | 16.6% |
| Gelir büyüme oranı | 13.2% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 02 Jul 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Anlatı Güncellemesi • Jun 11
MLSS: Expanding Clinical Adoption And New Capital Raise Will Drive Upside
Analysts have maintained their $1.00 price target for Milestone Scientific, noting only minor adjustments to the discount rate, profit margin assumptions, and future P/E inputs, rather than any broad change in outlook. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue in the range of US$9.8 million to US$10.2 million, citing double digit growth driven by commercial adoption across dental and medical segments.Anlatı Güncellemesi • May 27
MLSS: Medical Adoption And New Capital Raise Will Support Future Upside
Analysts have adjusted their price target on Milestone Scientific to $1.00, supported by updated assumptions that include a slightly lower discount rate, revised revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue of US$9.8 million to US$10.2 million, tied to commercial adoption in both dental and medical segments (Corporate Guidance).Anlatı Güncellemesi • May 04
MLSS: Expanded Share Authorization And Private Placement Will Support Future Upside
Milestone Scientific's analyst price target has been adjusted slightly, with analysts pointing to small refinements in the discount rate, long term profit margin assumptions and future P/E expectations as key drivers of the updated valuation. What's in the News Entered a securities purchase agreement for a private placement of 7,962,963 units at $0.27 per unit, for gross proceeds of about $2.15m.Anlatı Güncellemesi • Apr 18
MLSS: Expanded Share Authorization Will Support Future Upside As Guidance And PE Strengthen
Analysts have adjusted their price target on Milestone Scientific to reflect a modest change in the assumed discount rate and profit margin. They are keeping fair value at $1.00 while updating their future P/E outlook to 72.06x based on the latest inputs.Anlatı Güncellemesi • Apr 03
MLSS: Expanded Share Authorization Will Support Future Upside As Revenue Guidance Strengthens
Analysts have modestly adjusted their price target on Milestone Scientific to reflect updated views on slightly different revenue growth expectations, profit margin assumptions and a revised forward P/E profile, while keeping the fair value estimate broadly aligned with prior levels in dollar terms. What's in the News Management issued earnings guidance for the year ending December 31, 2026, with expected total revenue in a range of US$9.8 million to US$10.2 million, citing broadening commercial adoption in both dental and medical segments (company guidance).Anlatı Güncellemesi • Mar 19
MLSS: Expanded Share Authorization Will Support Future Upside From Current Levels
Analysts have modestly adjusted their price target on Milestone Scientific to reflect updated views on discount rates, profit margins, and future P/E expectations, while keeping the fair value estimate unchanged at $1.00 per share. What's in the News The company filed a Certificate of Amendment to its Restated Certificate of Incorporation in Delaware on March 10, 2026, increasing authorized common stock from 100,000,000 to 125,000,000 (Key Developments).Anlatı Güncellemesi • Mar 05
MLSS: Shares Will Likely Rise As Expanded Authorization Supports Undervaluation
Analysts have modestly raised their price target on Milestone Scientific to $1.00. The change reflects slightly higher assumed discount rates and price-to-earnings expectations, along with a marginally lower profit margin outlook in their updated models.Anlatı Güncellemesi • Feb 18
MLSS: Shares Will Likely Rise As Share Authorization Supports Undervaluation
Analysts have nudged their price target on Milestone Scientific slightly higher to $1.00, reflecting small tweaks to the discount rate, profit margin assumptions, and future P/E inputs in their models. What's in the News Shareholders ratified the appointment of CBIZCPA P.C. as Milestone Scientific Inc.'s independent auditors for the fiscal year ending December 31, 2025, at the AGM held on December 18, 2025 (Key Developments).Anlatı Güncellemesi • Feb 03
MLSS: Shares Will Likely Rise As Increased Share Authorization Supports Undervaluation
Analysts have adjusted their price target on Milestone Scientific to align with updated assumptions around discount rates, profit margins, and future P/E expectations. This has led to a modest shift in the projected valuation range expressed in US$ terms.Anlatı Güncellemesi • Jan 20
MLSS: Shares Will Likely Rise As Auditor Approval Supports Undervaluation
Analysts have slightly lifted their price target on Milestone Scientific to around US$1.00, citing small tweaks to their discount rate, profit margin outlook, and a projected future P/E of about 71x as the main drivers of the updated view. What's in the News Shareholders approved CBIZCPA P.C. as Milestone Scientific Inc.'s independent auditor for the fiscal year ending December 31, 2025, at the AGM held on December 18, 2025 (AGM filing).Anlatı Güncellemesi • Jan 06
MLSS: Shares Will Likely Rise As Listing Plan Supports Undervaluation
Analysts have made a modest adjustment to their price target on Milestone Scientific, keeping fair value anchored at US$1.00 while fine tuning assumptions around discount rate, revenue growth, profit margin and future P/E to reflect updated views on the company’s risk profile and earnings power. What's in the News At the December 18, 2025 AGM, shareholders approved an amendment to Milestone Scientific's Restated Certificate of Incorporation to increase authorized common shares from 100,000,000 to 125,000,000 (AGM filing).Anlatı Güncellemesi • Dec 19
MLSS: Shares Will Likely Rise As Listing Compliance Risks Ease
Analysts have modestly increased their price target on Milestone Scientific to reflect a slightly lower perceived risk in future cash flows, despite trimming long term profit margin assumptions and applying a higher forward earnings multiple. What's in the News Proposed amendment to the Restated Certificate of Incorporation to increase authorized common shares from 100 million to 125 million, expanding potential equity financing capacity (company filing).Anlatı Güncellemesi • Dec 04
MLSS: Shares Will Likely Rebound As NYSE Compliance Plan Progresses
Analysts have trimmed their price target on Milestone Scientific from 1.13 dollars to 1.00 dollars, citing slightly slower expected revenue growth and a modestly lower valuation multiple. This is partially offset by stable profit margin assumptions and a marginally reduced discount rate.Anlatı Güncellemesi • Nov 20
MLSS: Shares Will Face Key NYSE American Compliance Decision by 2027
Analysts have revised their price target for Milestone Scientific downward from $1.63 to $1.13. They cite lower projected revenue growth and a higher discount rate as key factors influencing their updated outlook.Anlatı Güncellemesi • Aug 19
CompuFlo Epidural System Will Unlock New Global Opportunities
The downward revision in Milestone Scientific’s price target reflects materially lower revenue growth expectations, leading to a drop in projected fair value from $2.12 to $1.62. What's in the News Eric C.
Yeni Anlatı • Apr 07
CompuFlo Epidural System Will Unlock New Global Opportunities
Strategic partnerships and regulatory approvals are expanding market access for the CompuFlo Epidural System, potentially driving significant revenue growth.Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2027 | 11 | -3 | N/A | 0 | 2 |
| 12/31/2026 | 10 | -3 | N/A | -1 | 2 |
| 3/31/2026 | 9 | -5 | -2 | -2 | N/A |
| 12/31/2025 | 9 | -6 | -3 | -3 | N/A |
| 9/30/2025 | 9 | -7 | -4 | -4 | N/A |
| 6/30/2025 | 9 | -7 | -5 | -5 | N/A |
| 3/31/2025 | 9 | -5 | -3 | -3 | N/A |
| 12/31/2024 | 9 | -5 | -3 | -3 | N/A |
| 9/30/2024 | 9 | -5 | -3 | -3 | N/A |
| 6/30/2024 | 8 | -5 | -3 | -3 | N/A |
| 3/31/2024 | 9 | -7 | -5 | -5 | N/A |
| 12/31/2023 | 10 | -7 | -5 | -5 | N/A |
| 9/30/2023 | 10 | -7 | -5 | -5 | N/A |
| 6/30/2023 | 10 | -7 | -5 | -5 | N/A |
| 3/31/2023 | 9 | -8 | -7 | -7 | N/A |
| 12/31/2022 | 9 | -9 | -6 | -6 | N/A |
| 9/30/2022 | 9 | -8 | -5 | -5 | N/A |
| 6/30/2022 | 9 | -8 | -6 | -6 | N/A |
| 3/31/2022 | 10 | -8 | -5 | -5 | N/A |
| 12/31/2021 | 10 | -7 | -4 | -4 | N/A |
| 9/30/2021 | 10 | -7 | -4 | -4 | N/A |
| 6/30/2021 | 9 | -6 | -5 | -5 | N/A |
| 3/31/2021 | 7 | -7 | -7 | -7 | N/A |
| 12/31/2020 | 5 | -7 | -7 | -7 | N/A |
| 9/30/2020 | 6 | -9 | -7 | -7 | N/A |
| 6/30/2020 | 6 | -10 | -5 | -5 | N/A |
| 3/31/2020 | 8 | -8 | -3 | -3 | N/A |
| 12/31/2019 | 8 | -8 | N/A | -2 | N/A |
| 9/30/2019 | 10 | -4 | N/A | -1 | N/A |
| 6/30/2019 | 10 | -6 | N/A | -1 | N/A |
| 3/31/2019 | 10 | -6 | N/A | -1 | N/A |
| 12/31/2018 | 10 | -7 | N/A | -2 | N/A |
| 9/30/2018 | 8 | -9 | N/A | -2 | N/A |
| 6/30/2018 | 9 | -6 | N/A | -2 | N/A |
| 3/31/2018 | 9 | -7 | N/A | -1 | N/A |
| 12/31/2017 | 11 | -5 | N/A | -1 | N/A |
| 9/30/2017 | 11 | -5 | N/A | -3 | N/A |
| 6/30/2017 | 11 | -6 | N/A | -3 | N/A |
| 3/31/2017 | 11 | -6 | N/A | -5 | N/A |
| 12/31/2016 | 10 | -6 | N/A | -5 | N/A |
| 9/30/2016 | 11 | -6 | N/A | -3 | N/A |
| 6/30/2016 | 11 | -5 | N/A | -4 | N/A |
| 3/31/2016 | 10 | -6 | N/A | -4 | N/A |
| 12/31/2015 | 9 | -5 | N/A | -3 | N/A |
| 9/30/2015 | 10 | -5 | N/A | -3 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: MLSS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Kazançlar ve Piyasa: MLSS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Yüksek Büyüme Kazançları: MLSS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Gelir ve Pazar: MLSS şirketinin gelirinin (yıllık 13.2% ) US pazarından (yıllık 12.5% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: MLSS şirketinin gelirinin (yıllık 13.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: MLSS 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/31 12:19 |
| Gün Sonu Hisse Fiyatı | 2026/07/31 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Milestone Scientific Inc. 3 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Bruce Jackson | Benchmark Company |
| Anthony Vendetti | Maxim Group |
| James Terwilliger | Northland Capital Markets |